Navigation Links
Initial Clinical Data Reveal Potential of Tasimelteon to Reset the Body Clock in Non-24-Hour Sleep-Wake Disorder
Date:1/26/2012

utilize some or all of its prior net operating losses and research and development credits; a loss of any of Vanda's key scientists or management personnel; losses incurred from product liability claims made against Vanda; a loss of rights to develop and commercialize Vanda's products or product candidates under its license and sublicense agreements and other factors that are described in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Vanda's annual report on Form 10-K for the fiscal year ended December 31, 2010 which is on file with the SEC and available on the SEC's website at www.sec.gov. In addition to the risks described above and in Vanda's annual report on Form 10-K and quarterly reports on Form 10-Q, other unknown or unpredictable factors also could affect Vanda's results. There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact:
Cristina Murphy
Senior Communications Manager
Vanda Pharmaceuticals Inc. '/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
2. MacuSight(TM) Announces Positive Initial Results From Phase 1 Study of Sirolimus in Diabetic Macular Edema
3. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
4. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
5. Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response
6. Treatment with PEGASYS(R)/COPEGUS(TM) Provides Hope for Hepatitis C Patients Whose Infection Did Not Initially Respond to Peg-Intron(R)/Ribavirin
7. Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases
8. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
9. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
10. ATS Medical Announces Initial Clinical Results of Stand-Alone Atrial Fibrillation Procedures Using ATS CryoMaze Product Line
11. Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron Pharmaceuticals, ... SAN and NYSE: SNY ) today announced ... in people with hypercholesterolemia met their primary efficacy endpoint ... lipoprotein cholesterol (LDL-C) at 24 weeks compared to placebo ... targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... and NEW YORK , July ... a developer of new products for oncology supportive care, ... ® , has been featured in an article on ... Symptoms in Head and Neck Cancers."  Dr. Steve ... insight on the growing demand seen in the oncology ...
(Date:7/30/2014)... July 30, 2014   Bluegrass Vascular Technologies ... innovating lifesaving devices and methods for vascular access, ... Series A financing, which was led by ... deal will allow Bluegrass Vascular to obtain CE ... enhance manufacturing capabilities, and proceed with US regulatory ...
Breaking Medicine Technology:Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8Access Pharmaceuticals Featured On OncLive.com 2Access Pharmaceuticals Featured On OncLive.com 3Bluegrass Vascular Technologies Raises $4.5M Series A Financing Led By Targeted Technology Funds 2
... July 27, 2011 Pharmaceutics International, Inc. (Pii), a ... it has added hot melt extrusion (HME) to its ... has purchased a 16mm and an 18mm Leistritz twin ... feasibility studies, using just a few grams of active ...
... Pharmaceuticals, Inc., announced today that the company has ... Angel Investors. The company is using the capital ... orphan receptor (ROR) modulators targeting TH17 T-lymphocytes for ... arthritis, multiple sclerosis, psoriasis and COPD. ...
Cached Medicine Technology:Pharmaceutics International, Inc. (Pii) Expands Drug Formulation and Manufacturing Capabilities with Hot Melt Extrusion Technology 2Visionary Pharmaceuticals, Inc., Announces Initial Seed Round Investments and the Launch of TH17 Autoimmune Disease Research Activities 2
(Date:7/30/2014)... Texas (PRWEB) July 30, 2014 “North ... key market data on the North America Contrast Media ... US dollars, and volume (in units) and average price ...     CT Injectors ,     Interventional Cardiology/Angio Injectors and ... (or contrast agent) is a substance used to enhance ...
(Date:7/30/2014)... for Vedic Studies (WAVES) conference is coming to Fairfield, ... 31 through Sunday, August 3. To watch the main ... the first time such a large and diverse group ... to explore the relevance of ancient Vedic knowledge in ... states of consciousness, and reflections on the various Vedic ...
(Date:7/30/2014)... Naomi Fried, PhD, and Alexis ... Directors of the American Telemedicine Association (ATA). ... has a mission to promote professional, ethical and ... information technology. , “Both Naomi Fried and Alexis ... expertise and are well known experts in their ...
(Date:7/30/2014)... 2014 The global digital pathology market was ... expected to grow at a CAGR of 11.8%, to reach ... digital pathology is growing and is expected to continue to ... scanners and image analysis software enable pathologists to be efficient ... In 2013, the North American market was valued at $128.9 ...
(Date:7/30/2014)... to suffer from depression as school-age children and young ... times more likely to suffer from the condition in ... depressed at very young ages, according to researchers at ... Their study is published in the July issue of ... the same old bad news about depression; it is ...
Breaking Medicine News(10 mins):Health News:Contrast Media Injectors Market in North America (US, Canada, Mexico) to 2020 Report Available at MarketOptimizer.org 2Health News:Contrast Media Injectors Market in North America (US, Canada, Mexico) to 2020 Report Available at MarketOptimizer.org 3Health News:Contrast Media Injectors Market in North America (US, Canada, Mexico) to 2020 Report Available at MarketOptimizer.org 4Health News:Vedic living in a modern world: International conference at Maharishi University 2Health News:Vedic living in a modern world: International conference at Maharishi University 3Health News:American Telemedicine Association Welcomes Two New Members to the Board of Directors 2Health News:Global Digital Pathology Market To See 11.8% CAGR to 2018 Says a New Research Report Available at ReportsnReports.com 2Health News:Global Digital Pathology Market To See 11.8% CAGR to 2018 Says a New Research Report Available at ReportsnReports.com 3Health News:Global Digital Pathology Market To See 11.8% CAGR to 2018 Says a New Research Report Available at ReportsnReports.com 4Health News:Global Digital Pathology Market To See 11.8% CAGR to 2018 Says a New Research Report Available at ReportsnReports.com 5Health News:Many depressed preschoolers still suffer in later school years 2Health News:Many depressed preschoolers still suffer in later school years 3
... ... movies for presentations, demonstrations and training. Version 7.5 introduces TrakMouse™, a new technology that ... , ... July 9, 2009 -- NetPlay Software releases Instant Demo v7.5 , a Windows ...
... Hollywood impact radiation perception? Can we treat cancer with ... the radiation exposure our astronauts receive during space travel ... and other questions will be addressed at the 54th ... will take place July 13-16, 2009 in Minneapolis, MN, ...
... ... change the law regarding personal injury accidents, New York personal injury lawyer David Perecman weighs ... New York, New ... Authority (MTA) spends millions to pay for damages caused to riders., , , , ,Unfortunately ...
... MedClean Technologies, Inc. (OTC Bulletin Board: MCLN) announced today ... the Company,s existing Common Stock Purchase Warrants with Initial Exercise ... Warrants") for newly issued Common Stock Purchase Warrants with a ... one-half the original number of shares of our common stock, ...
... TROIS-RIVIERES, Quebec, July 8 The Narconon drug rehab program ... with drug related charges due to their addiction. "You ... drug addiction, and just one day gets caught by police ... representative of Narconon Trois-Rivieres. "This is an all too ...
... Today, the American Hospital Association, Federation of American Hospitals ... White House and Senate Finance Chairman Max Baucus (D-MT) ... Cost savings is an important goal, supported by Physician ... owned hospitals. As always, physician hospitals will shoulder their ...
Cached Medicine News:Health News:Instant Demo Screen Recorder Now With TrakMouse™ Technology 2Health News:Health Physics Society 54th Annual Meeting 2Health News:As Lawsuits Hit the MTA, Personal Injury Lawyers Consider How Much is Too Much, or Too Little 2Health News:As Lawsuits Hit the MTA, Personal Injury Lawyers Consider How Much is Too Much, or Too Little 3Health News:MedClean Technologies Announces Results of Private Exchange Offer 2Health News:Drug Crimes in Canada Cause Continuing Problems for Small Communities 2Health News:Physician Hospitals of America Charges: Hospital Associations Bargain Away $155 Billion in Medicare Funding in Attempt to Destroy Physician Hospitals 2Health News:Physician Hospitals of America Charges: Hospital Associations Bargain Away $155 Billion in Medicare Funding in Attempt to Destroy Physician Hospitals 3
... incorporate a layered design unique in the ... to prevent stray electrosurgical burns along the ... failure or capacitive coupling; a well-documented patient ... all AEM Instruments provides a neutral return ...
... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
The Auto Suture™ ExtraHand™ balloon retractor is designed to be used during open surgery, gasless endoscopy, as well as endoscopy with gas insufflation....
Medicine Products: